Eli Lilly and Dermira have announced a definitive agreement for Lilly to acquire Dermira for roughly $1.1 billion, in an all-cash transaction. Dermira is a biopharma dedicated to developing new therapies for chronic skin conditions. The acquisition will expand Lilly’s immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. Lebrikizumab was granted Fast Track designation from the U.S. FDA in December 2019. Learn More